Patient Characteristics and Treatment Outcome
| Patient No. . | Age/Sex . | Skin Stage* . | Previous Therapy . | IL-12 Dose (ng/kg)† . | Weeks Treated . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | 69/M | T3 (large cell transformation) | topical mechlorethamine, retinoids, CHOP, IFN, photopheresis | 50-100 | 6 | Local response |
| 2 | 44/F | T2 | PUVA, topical mechlorethamine | 50-100 | 13 | Minor response |
| 3 | 69/M | T4 | IFN, retinoids, photopheresis | 100 | 1 | Withdrew |
| 4 | 76/F | T4 | IFN, photopheresis | 100-300 | 24 | Partial response |
| 5 | 70/F | T3 (large cell transformation) | Radiation, methotrexate | 100-300 | 8 | Local response |
| 6 | 71/M | T2 | PUVA, topical mechlorethamine | 100-300 | 24 | CR |
| 7 | 50/F | T2 | Topical steroids | 100 | 24 | CR |
| 8 | 80/M | T1 | PUVA, topical BCNU, mechlorethamine | 100 | 24 | PR |
| 9 | 56/M | T1 | Topical mechlorethamine, PUVA | 300 | 24 | PR |
| 10 | 64/M | T4 | Photopheresis, IFN, retinoids, GM-CSF | 300 | 10 | No response |
| Patient No. . | Age/Sex . | Skin Stage* . | Previous Therapy . | IL-12 Dose (ng/kg)† . | Weeks Treated . | Outcome . |
|---|---|---|---|---|---|---|
| 1 | 69/M | T3 (large cell transformation) | topical mechlorethamine, retinoids, CHOP, IFN, photopheresis | 50-100 | 6 | Local response |
| 2 | 44/F | T2 | PUVA, topical mechlorethamine | 50-100 | 13 | Minor response |
| 3 | 69/M | T4 | IFN, retinoids, photopheresis | 100 | 1 | Withdrew |
| 4 | 76/F | T4 | IFN, photopheresis | 100-300 | 24 | Partial response |
| 5 | 70/F | T3 (large cell transformation) | Radiation, methotrexate | 100-300 | 8 | Local response |
| 6 | 71/M | T2 | PUVA, topical mechlorethamine | 100-300 | 24 | CR |
| 7 | 50/F | T2 | Topical steroids | 100 | 24 | CR |
| 8 | 80/M | T1 | PUVA, topical BCNU, mechlorethamine | 100 | 24 | PR |
| 9 | 56/M | T1 | Topical mechlorethamine, PUVA | 300 | 24 | PR |
| 10 | 64/M | T4 | Photopheresis, IFN, retinoids, GM-CSF | 300 | 10 | No response |
Abbreviations: PUVA, psoralen, ultraviolet A; BCNU, carmustine.
T1 represents patch/plaque disease involving 10% or less of the skin surface, T2 is patch/plaque disease involving greater than 10% of the skin surface, T3 represents multiple tumors and T4 represents erythroderma.
Range of treatment doses indicates patient was dose escalated at week 4 of therapy.